Skip to main content
Erschienen in: Journal of Neurology 1/2013

01.01.2013 | Original Communication

Patent foramen ovale and atrial septal aneurysm can cause ischemic stroke in patients with antiphospholipid syndrome

verfasst von: Yasutaka Tanaka, Yuji Ueno, Nobukazu Miyamoto, Yoshiaki Shimada, Ryota Tanaka, Nobutaka Hattori, Takao Urabe

Erschienen in: Journal of Neurology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The purpose of the present study was to evaluate the contributions of embolic etiologies, patent foramen ovale (PFO) and atrial septal aneurysm (ASA) to the pathogenesis of ischemic stroke in patients with antiphospholipid syndrome (APS). We performed transesophageal echocardiography (TEE) examination for consecutive stroke patients who had been diagnosed with APS (APS group) to detect potential embolic sources. APS was diagnosed based on the modified Sapporo criteria. The control stroke group comprised age- and sex-matched cryptogenic stroke patients undergoing TEE. We assessed and compared the clinical characteristics and TEE findings between stroke patients with APS and control stroke groups. Among 582 patients, nine patients (nine women; mean age, 50 ± 18 years) were classified into the APS group. In 137 patients undergoing TEE, 41 age-matched female stroke patients were recruited to the control stroke group. Prevalences of PFO and ASA were significantly higher in the APS group than in the control stroke group (89 vs. 41 %, p = 0.027; 67 vs. 20 %, p = 0.015, respectively). Multiple logistic regression analysis showed that PFO (odds ratio (OR), 13.71; 95 % confidence interval (CI), 1.01–185.62; p = 0.049) and ASA (OR, 8.06; 95 % CI, 1.17–55.59; p = 0.034) were independently associated with the APS group. PFO and ASA were strongly associated with the APS group, and could thus represent potential embolic sources in ischemic stroke patients with APS.
Literatur
1.
Zurück zum Zitat Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346:752–763PubMedCrossRef Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346:752–763PubMedCrossRef
2.
Zurück zum Zitat Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306PubMedCrossRef Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306PubMedCrossRef
3.
Zurück zum Zitat Gromnica-Ihle E, Schossler W (2000) Antiphospholipid syndrome. Int Arch Allergy Immunol 123:67–76PubMedCrossRef Gromnica-Ihle E, Schossler W (2000) Antiphospholipid syndrome. Int Arch Allergy Immunol 123:67–76PubMedCrossRef
4.
Zurück zum Zitat Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311PubMedCrossRef Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311PubMedCrossRef
5.
Zurück zum Zitat Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336:177–178PubMedCrossRef Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336:177–178PubMedCrossRef
6.
Zurück zum Zitat Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027PubMedCrossRef Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027PubMedCrossRef
7.
Zurück zum Zitat The antiphospholipid antibodies in stroke study (APASS) group (1993) Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 43:2069–2073CrossRef The antiphospholipid antibodies in stroke study (APASS) group (1993) Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 43:2069–2073CrossRef
8.
Zurück zum Zitat Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Hebel JR, Kittner SJ (2002) Antiphospholipid antibodies and stroke in young women. Stroke 33:2396–2400PubMedCrossRef Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Hebel JR, Kittner SJ (2002) Antiphospholipid antibodies and stroke in young women. Stroke 33:2396–2400PubMedCrossRef
9.
Zurück zum Zitat Munts AG, van Genderen PJ, Dippel DW, van Kooten F, Koudstaal PJ (1998) Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 245:21–25PubMedCrossRef Munts AG, van Genderen PJ, Dippel DW, van Kooten F, Koudstaal PJ (1998) Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 245:21–25PubMedCrossRef
10.
Zurück zum Zitat Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ (2001) Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 32:1701–1706PubMedCrossRef Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ (2001) Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 32:1701–1706PubMedCrossRef
11.
Zurück zum Zitat Janardhan V, Wolf PA, Kase CS, Massaro JM, D’Agostino RB, Franzblau C, Wilson PW (2004) Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham Cohort and Offspring Study. Stroke 35:736–741PubMedCrossRef Janardhan V, Wolf PA, Kase CS, Massaro JM, D’Agostino RB, Franzblau C, Wilson PW (2004) Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham Cohort and Offspring Study. Stroke 35:736–741PubMedCrossRef
12.
Zurück zum Zitat Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y (2004) Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies-co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 91:967–976PubMed Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y (2004) Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies-co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 91:967–976PubMed
13.
Zurück zum Zitat Pierangeli SS, Harris EN (2003) Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 12:539–545PubMedCrossRef Pierangeli SS, Harris EN (2003) Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 12:539–545PubMedCrossRef
14.
Zurück zum Zitat Lonnebakken MT, Gerdts E (2008) Libman–Sacks endocarditis and cerebral embolization in antiphospholipid syndrome. Eur J Echocardiogr 9:192–193PubMedCrossRef Lonnebakken MT, Gerdts E (2008) Libman–Sacks endocarditis and cerebral embolization in antiphospholipid syndrome. Eur J Echocardiogr 9:192–193PubMedCrossRef
15.
Zurück zum Zitat Lockshin M, Tenedios F, Petri M, McCarty G, Forastiero R, Krilis S, Tincani A, Erkan D, Khamashta MA, Shoenfeld Y (2003) Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 12:518–523PubMedCrossRef Lockshin M, Tenedios F, Petri M, McCarty G, Forastiero R, Krilis S, Tincani A, Erkan D, Khamashta MA, Shoenfeld Y (2003) Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 12:518–523PubMedCrossRef
16.
Zurück zum Zitat Williamson JM, Dalton RS, Chester JF (2008) Popliteal venous aneurysm causing pulmonary embolism and paradoxical embolisation in a patient with antiphospholipid syndrome. Eur J Vasc Endovasc Surg 36:227–229PubMedCrossRef Williamson JM, Dalton RS, Chester JF (2008) Popliteal venous aneurysm causing pulmonary embolism and paradoxical embolisation in a patient with antiphospholipid syndrome. Eur J Vasc Endovasc Surg 36:227–229PubMedCrossRef
17.
Zurück zum Zitat Okura H, Tomon M, Nishiyama S, Yoshikawa T (2000) Patent foramen ovale and “Catastrophic” Antiphospholipid syndrome. Intern Med 39:83PubMedCrossRef Okura H, Tomon M, Nishiyama S, Yoshikawa T (2000) Patent foramen ovale and “Catastrophic” Antiphospholipid syndrome. Intern Med 39:83PubMedCrossRef
18.
Zurück zum Zitat Ago T, Ooboshi H, Kitazono T, Imamura T, Takada J, Ibayashi S, Iida M (2004) Brain infarction associated with antiphospholipid antibody syndrome caused by paradoxical embolism through patent foramen ovale. J Neurol 251:757–759PubMedCrossRef Ago T, Ooboshi H, Kitazono T, Imamura T, Takada J, Ibayashi S, Iida M (2004) Brain infarction associated with antiphospholipid antibody syndrome caused by paradoxical embolism through patent foramen ovale. J Neurol 251:757–759PubMedCrossRef
19.
Zurück zum Zitat Thompson T, Evans W (1930) Paradoxical embolism. Q J Med 23:135–137CrossRef Thompson T, Evans W (1930) Paradoxical embolism. Q J Med 23:135–137CrossRef
20.
Zurück zum Zitat Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O’Fallon WM, Pascoe RD, Enriquez-Sarano M, Seward JB, Covalt JL, Sicks JD, Wiebers DO (1999) Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke prevention: assessment of risk in a community. Mayo Clin Proc 74:862–869PubMedCrossRef Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O’Fallon WM, Pascoe RD, Enriquez-Sarano M, Seward JB, Covalt JL, Sicks JD, Wiebers DO (1999) Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke prevention: assessment of risk in a community. Mayo Clin Proc 74:862–869PubMedCrossRef
21.
Zurück zum Zitat Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345:1740–1746PubMedCrossRef Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345:1740–1746PubMedCrossRef
22.
Zurück zum Zitat Bonati LH, Kessel-Schaefer A, Linka AZ, Buser P, Wetzel SG, Radue EW, Lyrer PA, Engelter ST (2006) Diffusion-weighted imaging in stroke attributable to patent foramen ovale: significance of concomitant atrial septum aneurysm. Stroke 37:2030–2034PubMedCrossRef Bonati LH, Kessel-Schaefer A, Linka AZ, Buser P, Wetzel SG, Radue EW, Lyrer PA, Engelter ST (2006) Diffusion-weighted imaging in stroke attributable to patent foramen ovale: significance of concomitant atrial septum aneurysm. Stroke 37:2030–2034PubMedCrossRef
23.
Zurück zum Zitat Fujimoto S, Toyoda K, Jinnouchi J, Yasaka M, Kitazono T, Okada Y (2011) Differences in diffusion-weighted image and transesophageal echocardiographical findings in cardiogenic, paradoxical and aortogenic brain embolism. Cerebrovasc Dis 32:148–154PubMedCrossRef Fujimoto S, Toyoda K, Jinnouchi J, Yasaka M, Kitazono T, Okada Y (2011) Differences in diffusion-weighted image and transesophageal echocardiographical findings in cardiogenic, paradoxical and aortogenic brain embolism. Cerebrovasc Dis 32:148–154PubMedCrossRef
24.
Zurück zum Zitat Ueno Y, Shimada Y, Tanaka R, Miyamoto N, Tanaka Y, Hattori N, Urabe T (2010) Patent foramen ovale with atrial septal aneurysm may contribute to white matter lesions in stroke patients. Cerebrovasc Dis 30:15–22PubMedCrossRef Ueno Y, Shimada Y, Tanaka R, Miyamoto N, Tanaka Y, Hattori N, Urabe T (2010) Patent foramen ovale with atrial septal aneurysm may contribute to white matter lesions in stroke patients. Cerebrovasc Dis 30:15–22PubMedCrossRef
25.
Zurück zum Zitat Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG (2007) Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 38:2070–2073PubMedCrossRef Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG (2007) Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 38:2070–2073PubMedCrossRef
26.
Zurück zum Zitat Iguchi Y, Kimura K, Kobayashi K, Ueno Y, Inoue T (2006) Ischaemic stroke with malignancy may often be caused by paradoxical embolism. J Neurol Neurosurg Psychiatry 77:1336–1339PubMedCrossRef Iguchi Y, Kimura K, Kobayashi K, Ueno Y, Inoue T (2006) Ischaemic stroke with malignancy may often be caused by paradoxical embolism. J Neurol Neurosurg Psychiatry 77:1336–1339PubMedCrossRef
27.
Zurück zum Zitat Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, Yasuda S, Koike T (2009) Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68:1030–1035PubMedCrossRef Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, Yasuda S, Koike T (2009) Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68:1030–1035PubMedCrossRef
28.
Zurück zum Zitat Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41PubMedCrossRef Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41PubMedCrossRef
29.
Zurück zum Zitat Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y (1988) Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 318:1148–1152PubMedCrossRef Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y (1988) Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 318:1148–1152PubMedCrossRef
30.
Zurück zum Zitat Moon RE, Camporesi EM, Kisslo JA (1989) Patent foramen ovale and decompression sickness in divers. Lancet 1:513–514PubMedCrossRef Moon RE, Camporesi EM, Kisslo JA (1989) Patent foramen ovale and decompression sickness in divers. Lancet 1:513–514PubMedCrossRef
31.
Zurück zum Zitat Cariou R, Tobelem G, Soria C, Caen J (1986) Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 314:1193–1194PubMedCrossRef Cariou R, Tobelem G, Soria C, Caen J (1986) Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 314:1193–1194PubMedCrossRef
32.
Zurück zum Zitat Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL (1995) Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96:2211–2219PubMedCrossRef Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL (1995) Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96:2211–2219PubMedCrossRef
33.
34.
Zurück zum Zitat Rajamani K, Chaturvedi S, Jin Z, Homma S, Brey RL, Tilley BC, Sacco RL, Thompson JL, Mohr JP, Levine SR (2009) Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study. Stroke 40:2337–2342PubMedCrossRef Rajamani K, Chaturvedi S, Jin Z, Homma S, Brey RL, Tilley BC, Sacco RL, Thompson JL, Mohr JP, Levine SR (2009) Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS-APASS study. Stroke 40:2337–2342PubMedCrossRef
35.
Zurück zum Zitat Dodge SM, Hassell K, Anderson CA, Keller J, Groves B, Carroll JD (2004) Antiphospholipid antibodies are common in patients referred for percutaneous patent foramen ovale closure. Catheter Cardiovasc Interv 61:123–127PubMedCrossRef Dodge SM, Hassell K, Anderson CA, Keller J, Groves B, Carroll JD (2004) Antiphospholipid antibodies are common in patients referred for percutaneous patent foramen ovale closure. Catheter Cardiovasc Interv 61:123–127PubMedCrossRef
36.
Zurück zum Zitat Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, Coste J, Mas JL (2002) Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA study. Atrial septal aneurysm. Stroke 33:706–711PubMedCrossRef Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, Coste J, Mas JL (2002) Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA study. Atrial septal aneurysm. Stroke 33:706–711PubMedCrossRef
37.
Zurück zum Zitat Rigatelli G (2007) Patent foramen ovale: the evident paradox between the apparently simple treatment and the really complex pathophysiology. J Cardiovasc Med (Hagerstown) 8:300–304CrossRef Rigatelli G (2007) Patent foramen ovale: the evident paradox between the apparently simple treatment and the really complex pathophysiology. J Cardiovasc Med (Hagerstown) 8:300–304CrossRef
38.
Zurück zum Zitat Berthet K, Lavergne T, Cohen A, Guize L, Bousser MG, Le Heuzey JY, Amarenco P (2000) Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 31:398–403PubMedCrossRef Berthet K, Lavergne T, Cohen A, Guize L, Bousser MG, Le Heuzey JY, Amarenco P (2000) Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 31:398–403PubMedCrossRef
39.
Zurück zum Zitat Aguilar JA, Summerson C (2000) Intracardiac thrombus in antiphospholipid antibody syndrome. J Am Soc Echocardiogr 13:873–875PubMedCrossRef Aguilar JA, Summerson C (2000) Intracardiac thrombus in antiphospholipid antibody syndrome. J Am Soc Echocardiogr 13:873–875PubMedCrossRef
40.
Zurück zum Zitat Coppock MA, Safford RE, Danielson GK (1988) Intracardiac thrombosis, phospholipid antibodies, and two-chambered right ventricle. Br Heart J 60:455–458PubMedCrossRef Coppock MA, Safford RE, Danielson GK (1988) Intracardiac thrombosis, phospholipid antibodies, and two-chambered right ventricle. Br Heart J 60:455–458PubMedCrossRef
41.
Zurück zum Zitat Rigatelli G, Aggio S, Cardaioli P, Braggion G, Giordan M, Dell’avvocata F, Chinaglia M, Roncon L, Chen JP (2009) Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: an alternative concurrent mechanism for arterial embolism. JACC Cardiovasc Interv 2:655–662PubMedCrossRef Rigatelli G, Aggio S, Cardaioli P, Braggion G, Giordan M, Dell’avvocata F, Chinaglia M, Roncon L, Chen JP (2009) Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: an alternative concurrent mechanism for arterial embolism. JACC Cardiovasc Interv 2:655–662PubMedCrossRef
Metadaten
Titel
Patent foramen ovale and atrial septal aneurysm can cause ischemic stroke in patients with antiphospholipid syndrome
verfasst von
Yasutaka Tanaka
Yuji Ueno
Nobukazu Miyamoto
Yoshiaki Shimada
Ryota Tanaka
Nobutaka Hattori
Takao Urabe
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 1/2013
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6613-4

Weitere Artikel der Ausgabe 1/2013

Journal of Neurology 1/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.